Krystal Biotech, Inc. (NASDAQ: KRYS) is a Healthcare company (Biotechnology) with a market capitalization of $8.8B. The Maz Rating grades it against the other companies in its sector.
Krystal Biotech, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $298.55, Krystal Biotech, Inc. trades at 38.8x trailing earnings, 18.8x sales and 6.1x book value, with an EV/EBITDA of 33.2. Over the last twelve months it generated about $472M of revenue and $228M of net income. It runs a gross margin of 93.4%, an operating margin of 48.4% and a net margin of 47.9%. It shows return on equity of 17.0%, return on invested capital of 13.7% and a free cash flow yield of 3.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 7.89. Over the past 52 weeks the share price ranged from $202.99 to $382.54, with a beta of 0.50.
Krystal Biotech, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 18 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.